IDH1 and posterior cortical atrophy: Concentrations used herein (1–5 μm) to inhibit PCa cells with wild‐type IDH1 correspond to the concentrations used to specifically kill acute myelogenous leukaemia (AML) cells with mutant IDH1 with no impact on AML cells with wild‐type IDH1 [38].